Osmotica Pharmaceuticals plc Reports Third Quarter 2020 Results and Provides Business Updates
10 nov. 2020 16h05 HE
|
Osmotica Holdings US LLC
Third quarter 2020 total revenue of $57.2 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired...
Osmotica Pharmaceuticals plc to Provide Third Quarter 2020 Business and Financial Update on November 10, 2020
05 nov. 2020 17h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Upneeq™ (oxymetazoline hydrochloride, 0.1% solution) for Acquired Ptosis
01 oct. 2020 13h32 HE
|
Osmotica Holdings US LLC
-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired...
Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference
02 sept. 2020 16h30 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business Updates
11 août 2020 16h05 HE
|
Osmotica Holdings US LLC
Second quarter 2020 total revenue of $37.5 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired...
Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020
06 août 2020 20h00 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
28 juil. 2020 06h50 HE
|
Osmotica Holdings US LLC
OSAKA, Japan and BRIDGEWATER, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc...
Osmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release Tablets
20 juil. 2020 06h50 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully...
Osmotica Announces Pricing of Public Offering of Ordinary Shares
13 juil. 2020 21h52 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the...
Osmotica Announces Proposed Public Offering of Ordinary Shares
13 juil. 2020 16h15 HE
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the...